CODA Biotherapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CODA Biotherapeutics's estimated annual revenue is currently $2.8M per year.(i)
  • CODA Biotherapeutics's estimated revenue per employee is $155,000

Employee Data

  • CODA Biotherapeutics has 18 Employees.(i)
  • CODA Biotherapeutics grew their employee count by -53% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is CODA Biotherapeutics?

CODA Biotherapeutics' revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells. CODA's engineered receptors will be able to modulate the activity of virtually any cell in which the receptor is ectopically expressed, making them suitable for the treatment of many disorders. CODA can further tailor the therapy to a particular disease by simply changing the viral capsid, DNA regulatory elements, and route of administration.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$2.8M

Revenue (est)

-53%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CODA Biotherapeutics News

2022-03-22 - Pursuit of Scientific Challenges Drives New CODA CSO ...

Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics,...

2022-03-22 - CODA Biotherapeutics Names Susan Catalano, Ph.D., as ...

CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach by deploying a chemogenetic strategy for treating neurological...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0M18-14%$301.3M
#2
$188M18-44%$127.8M
#3
$2.8M18-18%N/A
#4
$1.7M19-5%N/A
#5
$3.8M20-77%N/A